Project Grant R34AI194337
Award Date 9/1/25
Completion Date 8/31/26
Dollars Obligated $259K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
- This federal Project Grant award of $300,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a therapeutic nucleic acid vaccine for chronic hepatitis B virus (HBV) infections in HIV/HBV co-infected individuals. The awardee, Orlance, Inc., a woman-owned small business in Seattle, Washington, is leveraging its innovative MACH-1 gene gun technology to efficiently deliver DNA...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $320,863 to Jericho Sciences, LLC to support the translational development of a small molecule therapeutic for the treatment of chronic hepatitis B virus (HBV) infection. The project aims to validate the proposed drug target, the hepatitis B X regulatory protein (HBx), which plays a critical role in HBV covalently...
- This $510,306 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of virus-host interactions for developing a cure against chronic hepatitis B virus (HBV) infections. The primary goal is to investigate the mechanisms by which interferon-alpha treatment can lead to a functional cure for HBV, as well as explore the impact of HBV...
- This $847,428 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to understand the mechanisms of hepatitis B virus (HBV) persistence and clearance in chronic hepatitis B patients, with a focus on evaluating intrahepatic cccDNA and integrated DNA. The primary awardee, Beth Israel Deaconess Medical Center, will conduct translational research to quantify cccDNA and integrated DNA levels,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $5,504,270 Cooperative Agreement to The Johns Hopkins University on September 26, 2025 under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The award will establish a multinational cohort of people with HIV and chronic hepatitis B (PWHHB) to apply novel technologies and advance a hepatitis B virus (HBV) functional cure. The project aims to characterize mechanisms of intrahepatic HBV...
- This $814,790 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to uncover the immune mechanisms underlying hepatitis B virus (HBV) surface antigen clearance, which can lead to a clinical cure for chronic HBV infection. The principal investigators at the University of California, San Francisco (UCSF) will leverage mouse models and clinical samples from HBV patients to conduct a...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $972,583 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Research Institute at Nationwide Children's Hospital in Ohio. The grant, titled "Defining Successful Intrahepatic CD4+ T Cell Responses Against the Hepatitis C Virus," aims to study protective CD4+ T cell responses in order to develop an effective vaccine against chronic Hepatitis C virus (HCV) infection....
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is funding the creation of a transgenic pig model susceptible to hepatitis B virus (HBV) infection. The $440,000 award aims to establish an immunocompetent pig model that can be used to advance the understanding of HBV biology and test curative strategies for chronic HBV infection. The project involves introducing the human HBV...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant to Partillion Bioscience Corp, a biotechnology company based in Los Angeles, California. The grant, funded under NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of advanced workflows utilizing Partillion's specialized hydrogel microparticle technology called "nanovials". The goal is to enable ultra high-throughput screening and functional...